A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Clinical trial NCT05327946 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05327946
- Sponsor
- Boehringer Ingelheim
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-17
- Primary completion
- 2024-07-16
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.